# US 12,599,620 B2 · Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,620 B2
- Document ID: US12599620B2
- Status: Granted
- Kind: B2
- Application number: 17/638,453
- Filed: 2020-08-31
- Published: 2022-10-27
- Granted: 2026-04-14
- Earliest claimed: 2019-08-30
- Assignees: Vestlandets Innovasjonsselskap AS
- Applicants: Vestlandets Innovasjonsselskap AS
- Inventors: Øystein Fluge; Olav Mella
- Web page: https://patentgrep.com/patent/US12599620B2

## CPC

- A61K 31/69: Boron compounds
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 16/2887: {against CD20}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present disclosure relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chronic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.

## Claims

### Claim 1

A method for the treatment of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) comprising administering to a subject in need thereof a therapeutically effective amount of a cytotoxic agent against plasma cells to reduce antibody production, wherein the cytotoxic agent is an antibody directed against CD38 and wherein the antibody directed against CD38 is Daratumumab.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said cytotoxic agent is adapted for systemic administration.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said cytotoxic agent is administered in a pharmaceutically effective dosage systemically.